Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Innate αβ T cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.

Hundeyin M, Kurz E, Mishra A, Kochen Rossi JA, Liudahl SM, Leis KR, Mehrotra H, Kim M, Torres LE, Ogunsakin A, Link J, Sears RC, Sivagnanam S, Goecks J, Islam KS, Dolgalev I, Savadkar S, Wang W, Aykut B, Leinwand J, Diskin B, Adam S, Israr M, Gelas M, Lish J, Chin K, Farooq MS, Wadowski B, Wu J, Shah S, Adeegbe DO, Pushalkar S, Vasudevaraja V, Saxena D, Wong KK, Coussens LM, Miller G.

Cancer Discov. 2019 Jul 2. pii: CD-19-0161. doi: 10.1158/2159-8290.CD-19-0161. [Epub ahead of print]

PMID:
31266770
2.

Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.

Ha D, Tanaka A, Kibayashi T, Tanemura A, Sugiyama D, Wing JB, Lim EL, Teng KWW, Adeegbe D, Newell EW, Katayama I, Nishikawa H, Sakaguchi S.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):609-618. doi: 10.1073/pnas.1812186116. Epub 2018 Dec 26.

3.

RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.

Wang W, Marinis JM, Beal AM, Savadkar S, Wu Y, Khan M, Taunk PS, Wu N, Su W, Wu J, Ahsan A, Kurz E, Chen T, Yaboh I, Li F, Gutierrez J, Diskin B, Hundeyin M, Reilly M, Lich JD, Harris PA, Mahajan MK, Thorpe JH, Nassau P, Mosley JE, Leinwand J, Kochen Rossi JA, Mishra A, Aykut B, Glacken M, Ochi A, Verma N, Kim JI, Vasudevaraja V, Adeegbe D, Almonte C, Bagdatlioglu E, Cohen DJ, Wong KK, Bertin J, Miller G.

Cancer Cell. 2018 Nov 12;34(5):757-774.e7. doi: 10.1016/j.ccell.2018.10.006.

PMID:
30423296
4.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

5.

Intron retention is a source of neoepitopes in cancer.

Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, Fugmann T, Wong KK, Van Allen EM.

Nat Biotechnol. 2018 Dec;36(11):1056-1058. doi: 10.1038/nbt.4239. Epub 2018 Aug 16.

6.

BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.

Adeegbe DO, Liu S, Hattersley MM, Bowden M, Zhou CW, Li S, Vlahos R, Grondine M, Dolgalev I, Ivanova EV, Quinn MM, Gao P, Hammerman PS, Bradner JE, Diehl JA, Rustgi AK, Bass AJ, Tsirigos A, Freeman GJ, Chen H, Wong KK.

Cancer Immunol Res. 2018 Oct;6(10):1234-1245. doi: 10.1158/2326-6066.CIR-18-0077. Epub 2018 Aug 7.

PMID:
30087114
7.

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer.

Li S, Liu S, Deng J, Akbay EA, Hai J, Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, Gutiérrez-Quiceno L, Zhang Y, Merlino AA, Quinn MM, Zeng Y, Yu X, Liu Y, Fan L, Aguirre AJ, Barbie DA, Yi X, Wong KK.

Clin Cancer Res. 2018 Oct 1;24(19):4854-4864. doi: 10.1158/1078-0432.CCR-17-3438. Epub 2018 Jun 26.

8.

NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.

Liu Y, Li Y, Liu S, Adeegbe DO, Christensen CL, Quinn MM, Dries R, Han S, Buczkowski K, Wang X, Chen T, Gao P, Zhang H, Li F, Hammerman PS, Bradner JE, Quayle SN, Wong KK.

Cancer Res. 2018 Jul 1;78(13):3709-3717. doi: 10.1158/0008-5472.CAN-18-0161. Epub 2018 May 14.

9.

MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.

Bouillez A, Adeegbe D, Jin C, Hu X, Tagde A, Alam M, Rajabi H, Wong KK, Kufe D.

Oncoimmunology. 2017 Jul 5;6(9):e1338998. doi: 10.1080/2162402X.2017.1338998. eCollection 2017.

10.

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, Castrillon J, Yuan GC, Poudel-Neupane N, Zhang H, Guerriero JL, Han S, Awad MM, Barbie DA, Ritz J, Jones SS, Hammerman PS, Bradner J, Quayle SN, Wong KK.

Cancer Discov. 2017 Aug;7(8):852-867. doi: 10.1158/2159-8290.CD-16-1020. Epub 2017 Apr 13.

11.

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.

Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, Kharbanda S, Wong KK, Kufe D.

Oncogene. 2017 Jul 13;36(28):4037-4046. doi: 10.1038/onc.2017.47. Epub 2017 Mar 13.

12.

The Lower Limit of Regulatory CD4+ Foxp3+ TCRβ Repertoire Diversity Required To Control Autoimmunity.

Yu A, Dee MJ, Adeegbe D, Dwyer CJ, Altman NH, Malek TR.

J Immunol. 2017 Apr 15;198(8):3127-3135. doi: 10.4049/jimmunol.1601966. Epub 2017 Mar 6.

13.

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, Van Allen EM.

Immunity. 2017 Feb 21;46(2):197-204. doi: 10.1016/j.immuni.2017.02.001.

14.

Regulatory T cells in cancer; can they be controlled?

Adeegbe DO, Nishikawa H.

Immunotherapy. 2015;7(8):843-6. doi: 10.2217/imt.15.52. Epub 2015 Aug 28. No abstract available.

15.

Detection of self-reactive CD8⁺ T cells with an anergic phenotype in healthy individuals.

Maeda Y, Nishikawa H, Sugiyama D, Ha D, Hamaguchi M, Saito T, Nishioka M, Wing JB, Adeegbe D, Katayama I, Sakaguchi S.

Science. 2014 Dec 19;346(6216):1536-40. doi: 10.1126/science.aaa1292.

PMID:
25525252
16.

Natural and induced T regulatory cells in cancer.

Adeegbe DO, Nishikawa H.

Front Immunol. 2013 Jul 11;4:190. doi: 10.3389/fimmu.2013.00190. eCollection 2013.

17.

In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice.

Adeegbe D, Serafini P, Bronte V, Zoso A, Ricordi C, Inverardi L.

Cell Transplant. 2011;20(6):941-54. doi: 10.3727/096368910X540621. Epub 2010 Nov 5.

PMID:
21054938
18.

Allogeneic T regulatory cell-mediated transplantation tolerance in adoptive therapy depends on dominant peripheral suppression and central tolerance.

Adeegbe D, Levy RB, Malek TR.

Blood. 2010 Mar 11;115(10):1932-40. doi: 10.1182/blood-2009-08-238584. Epub 2009 Dec 29.

19.

CD4(+) CD25(+) Foxp3(+) T regulatory cells with limited TCR diversity in control of autoimmunity.

Adeegbe D, Matsutani T, Yang J, Altman NH, Malek TR.

J Immunol. 2010 Jan 1;184(1):56-66. doi: 10.4049/jimmunol.0902379. Epub 2009 Nov 30.

20.

IL-2 family of cytokines in T regulatory cell development and homeostasis.

Malek TR, Yu A, Zhu L, Matsutani T, Adeegbe D, Bayer AL.

J Clin Immunol. 2008 Nov;28(6):635-9. doi: 10.1007/s10875-008-9235-y. Epub 2008 Aug 26.

PMID:
18726679
21.
22.

Quantitative assessment concerning the contribution of IL-2Rbeta for superantigen-mediated T cell responses in vivo.

Jin H, Gong D, Adeegbe D, Bayer AL, Rolle C, Yu A, Malek TR.

Int Immunol. 2006 Apr;18(4):565-72. Epub 2006 Mar 15.

PMID:
16540525
23.

Supplemental Content

Loading ...
Support Center